Helen I. Torley
2019
Compensation breakdown
| Non-Equity Incentive Plan | $712,296 |
|---|---|
| Option Awards | $2,184,128 |
| Salary | $761,000 |
| Stock Awards | $2,184,130 |
| Other | $15,572 |
| Total | $5,857,126 |
Torley received $2.2M in stock awards, accounting for 37% of the total pay in 2019.
Torley also received $712.3K in non-equity incentive plan, $2.2M in option awards, $761K in salary and $15.6K in other compensation.
Rankings
In 2019, Helen I. Torley's compensation ranked 1,776th out of 13,971 executives tracked by ExecPay. In other words, Torley earned more than 87.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,776 out of 13,971 | 87th |
Division Manufacturing | 633 out of 5,701 | 89th |
Major group Chemicals And Allied Products | 191 out of 2,200 | 91st |
Industry group Drugs | 153 out of 1,886 | 92nd |
Industry Biological Products, Except Diagnostic Substances | 35 out of 389 | 91st |
Pay ratio
| Helen I. Torley's Pay | $5,857,126 |
|---|---|
| Median Employee's Pay | $238,096 |
| Pay Ratio | 25to 1 |
In 2019, the annual total compensation of Helen I. Torley was $5,857,126.
The annual total compensation of the median employee at Halozyme Therapeutics was $238,096.
The ratio of Helen I. Torley's pay to the pay of median employee was therefore 25 to one.
Torley's colleagues
We found four more compensation records of executives who worked with Helen I. Torley at Halozyme Therapeutics in 2019.
2019
Alison Armour
Halozyme Therapeutics
Former Senior Vice President, Head of Research & Development
2019
Laurie Stelzer
Halozyme Therapeutics
Chief Financial Officer
2019
Benjamin Hickey
Halozyme Therapeutics
Former Senior Vice President, Chief Commercial Officer
2019
Harry Leonhardt
Halozyme Therapeutics
General Counsel
News
March 25, 2022
March 26, 2021
March 20, 2020
March 22, 2019